55775-97-8

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dichloro-3-nitrobenzoic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds for potential therapeutic applications. Its unique structure allows for the creation of new molecules with potential benefits in the treatment of diseases.
Used in the Synthesis of DNA-Binding Antitumor Agents:
2,6-Dichloro-3-nitrobenzoic acid is used as a starting material for the preparation of 9-chloro-2-methoxy-6-nitro-5,10-dihydrobenzo[b][1,5]naphthyridin-10-one, which is a compound required for the synthesis of potential DNA-binding antitumor agents. These agents may have significant implications in the development of novel cancer treatments.
Used in the Synthesis of Pyrazoloacridines:
DCNBA is also utilized in the preparation of 2-(aminoalkyl)-5-nitropyrazolo[3,4,5-kl]acridines, a class of compounds with potential applications in the pharmaceutical industry, particularly in the development of new drugs with various therapeutic properties.
Used in Analytical Chemistry:
The FT-IR and Raman spectra of 2,6-dichloro-3-nitrobenzoic acid have been investigated, which indicates its potential use in analytical chemistry for the identification and characterization of related compounds through spectral analysis. This can be valuable in both research and quality control processes within the chemical and pharmaceutical industries.

InChI:InChI=1/C7H3Cl2NO4/c8-3-1-2-4(10(13)14)6(9)5(3)7(11)12/h1-2H,(H,11,12)

Upstream product

• 50-30-6 2,6-dichlorobenzoic acid 
• 7664-93-9 sulfuric acid 
• 7697-37-2 nitric acid 
• 20443-98-5 2,6-Dichlorobenzyl bromide 

Downstream Products

• 114615-19-9 6-Chloro-2-(2-methoxy-phenylsulfanyl)-3-nitro-benzoic acid 
• 99009-60-6 2-[(4-butoxyphenyl)amino]-6-chloro-3-nitrobenzoic acid 
• 99009-51-5 2-Chloro-5-nitro-6-[[4-(phenylmethoxy)phenyl]amino]benzoic acid 
• 99140-54-2 2-(3-Benzyloxy-phenylamino)-6-chloro-3-nitro-benzoic acid 
• 99009-62-8 6-chloro-2-<<<4-(2-diethylamino)ethoxy>phenyl>amino>-3-nitrobenzoic acid 
• 144346-81-6 2-(4-Allyloxy-phenylamino)-6-chloro-3-nitro-benzoic acid 
• 99009-58-2 6-chloro-3-nitro-2-[(4-propoxyphenyl)amino]benzoic acid 
• 144346-85-0 2-(4-Benzyloxy-3-chloro-phenylamino)-6-chloro-3-nitro-benzoic acid 
• 99009-55-9 6-chloro-2[(2-methoxyphenyl)amino]-3-nitrobenzoic acid 
• 55830-46-1 6-chloro-2-[(4-methylphenyl)amino]-3-nitrobenzoic acid 
• 55776-14-2 6-chloro-2-<(4-chlorophenyl)amino>-3-nitrobenzoic acid 
• 144346-84-9 2-(Benzo[1,3]dioxol-5-ylamino)-6-chloro-3-nitro-benzoic acid 
• 99009-73-1 6-chloro-2-<<4-(dimethylamino)phenyl>amino>-3-nitrobenzoic acid 
• 99009-70-8 6-chloro-2[(3-chloro-4-methoxyphenyl)amino]-3-nitrobenzoic acid 

Relevant academic research and scientific papers

Structure-activity relationship of novel acridone derivatives as antiproliferative agents

Unlike other DNA topoisomerase II (topo II) inhibitors, our recently identified acridone derivative E17 exerted strong cytotoxic activity by inhibiting topo II without causing topo II degradation and DNA damage, which promoted us to explore more analogues

Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?

Βradykinin stimulation of B2 receptor is known to activate the oncogenic ERK pathway and overexpression of bradykinin receptors B1 and B2 has been reported to occur in glioma, colorectal and cervical cancers. B1R and B2R antagonists have been shown to reverse tumor proliferation and invasion. Paradoxically, B1R and B2R agonism has also been reported to elicit antiproliferative benefits. In order to complement the data accumulated to date with the natural substrate bradykinin and peptidic B2R antagonists, we decided to examine for the first time the response elicited by B2R stimulation in breast cancer lines with a non-peptidic small molecule B2R agonist. We synthesized and assessed the highly selective and potent B2R partial agonist FR-190997 in MCF-7 and MDA-MBA-231 breast cancer lines and found it possessed significant antiproliferative activity (IC50 2.14 and 0.08 μΜ, respectively). The modular nature of FR-190997 allowed us to conduct a focused SAR study and discover compound 10 which exhibits subnanomolar antiproliferative activity (IC 50 0.06 nΜ) in the TNBC MDA-MBA-231 cell line. This performance surpasses, in most cases by several orders of magnitude, those of established anticancer agents and FDA-approved breast cancer drugs. In line with the established literature we suggest that this remarkable activity precipitates from a dual mode of action involving agonist-induced receptor internalization/degradation combined with sequestration of functional intracellular B2 receptors and inhibition of the associated endosomal signaling. The latter mode may be realized by appropriate ligands regardless of B2R agonist/antagonist designation which only relates to membrane residing GCPRs. Under this prism the controversy over the antiproliferative effects of B2 agonists and antagonists is potentially neutralized.

Synthesis method of anti-cancer drug intermediate methyl 2-fluoro-3-aminobenzoate

The invention discloses a synthetic method of 2-fluoro-3-methyl aminobenzoate, and belongs to the technical field of synthesis of medical intermediates. According to the method, 2, 6-dichlorobenzoic acid is taken as a raw material, 2, 6-dichloro-3-nitrobe

HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A' B, D, R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

Novel inhibitors of NRH:Quinone oxidoreductase 2 (NQO2): Crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones

Imidazoacridin-6-ones are shown to be potent nanomolar inhibitors of the enzyme NQO2. By use of computational molecular modeling, a reliable QSAR was established, relating inhibitory potency with calculated binding affinity. Further, crystal structures of

Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2

A range of triazoloacridin-6-ones functionalized at C5 and C8 have been synthesized and evaluated for ability to inhibit NQO1 and NQO2. The compounds were computationally docked into the active site of NQO1 and NQO2, and calculated binding affinities were

Substituted benzimidazoles useful as angiotension II receptor antagonists

Angiotensin II receptor antagonists having the formula: STR1 which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

Chromatographic Separation of Enantiomers and Barriers to Enantiomerization of Axially Chiral Aromatic Carboxamides

The enantiomers (M) and (P) of a series of similar aromatic carboxamides have been, for the first time, investigated analytically and enriched preparatively by liquid chromatography on triacetylcellulose.Enantiomeric purities (7-99percent), specific rotations, and barriers to rotation about the C(sp2)-C(sp2) bond (87 - 120 kJ/mol, Table 5) were determined.These energies are discussed in terms of the size of ortho substituents and of the buttressing effects by meta substituents.

Process for the production of nitro derivatives of aromatic compounds

Nitroderivates of aromatic compounds which are difficult to nitrate, can readily be obtained by nitration providing that the aromatic compound is treated with nitric acid or another nitrating agent in the presence of aliphatic or cycloaliphatic hydrocarbons monosubstituted or polysubstituted by halogen, the nitro group or an alkyl sulphonyl group, and the nitro derivative formed subsequently isolated.